siehe der Abschnitt "
BMS has also registered Phase 3 trials of KarXT and KarX-EC to start in early 2026 for schizophrenia in adolescents, cognitive impairment associated with schizophrenia, mania in people with bipolar disorder, and irritability associated with autism spectrum disorder.
For details on Kar-XT trials, see clinicaltrials.gov.",
wobei BMS wohl für den Namen des Pharmaunternehmens steht, das Karuna Therapeutics aufgekauft hat.